Mechanism [ftcn]    
Action [ftcn]    
calcium antagonist [phsu]    
Triglyceride Metabolism [moft]    
Evaluated [hlca]    
Dihydropyridine calcium antagonist [phsu]    
TYPE [qlco]    
plasma lipid [lbpr]    
Levels [qlco]    
OBESE [dsyn]    
Rats, Zucker [mamm]    
Rats [mamm]    
Treated [ftcn]    
Orally [spco]    
mg/kg/day [qnco]    
7 days [tmco]    
PLASMA [bdsu]    
TG [lbpr]    
Rich [qlco]    
Levels [qlco]    
DOSE [qnco]    
Decreased [qnco]    
Increased [qnco]    
Total Cholesterol [lbpr]    
Low density Lipoprotein level [lbpr]    
Mechanism [ftcn]    
Decrease [qlco]    
PLASMA [bdsu]    
TG [lbpr]    
Levels [qlco]    
Examined [fndg]    
Synthesis [biof]    
secretion [biof]    
TG [lbpr]    
Rich [qlco]    
human cell [lbtr]    
Intestinal [bpoc]    
Line 2 [fndg]    
Association [menp]    
Degradation [ftcn]    
Human cells [lbtr]    
HEPATOBLASTOMA [neop]    
Caco-2 Cells [cell]    
Membrane [tisu]    
Filter [mnob]    
Added [ftcn]    
APICAL [spco]    
Side [spco]    
Inhibited [qlco]    
secretion [biof]    
TG [lbpr]    
Suppressed [ftcn]    
secretion [biof]    
HepG2 Cells [cell]    
Increased [qnco]    
Cellular [cell]    
Uptake [phsf]    
Suggest [idcn]    
Decreased [qnco]    
PLASMA [bdsu]    
TG [lbpr]    
INHIBITION [menp]    
Intestinal Secretion [bdsu]    
Enhancement [topp]    
Hepatic [blor]    
Uptake [phsf]    
treatment [ftcn]    
hypertensive [fndg]    
Patients [podg]    
HYPERTRIGLYCERIDEMIA [dsyn]    
Risk Factors [qnco]    
coronary heart disease [dsyn]    
